A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
Public ClinicalTrials.gov record NCT07207707. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it aims to answer are: * What is the safe dose of KQB548? * Does KQB548 decrease the size of the tumor? * What happens to KQB548 in the body?
Study identification
- NCT ID
- NCT07207707
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 78 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 16, 2025 (Actual)
- Primary completion
- Sep 2026 (Estimated)
- Completion
- Mar 2027 (Estimated)
- Last update posted
- May 20, 2026
2025 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Diego | La Jolla | California | 92037 | Recruiting |
| University of California, Los Angeles | Los Angeles | California | 90095 | Recruiting |
| SCRI - Denver | Denver | Colorado | 80218 | Recruiting |
| University of Miami - Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | Recruiting |
| START Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| The Christ Hospital | Cincinnati | Ohio | 45219 | Recruiting |
| NEXT Oncology - Austin | Austin | Texas | 78758 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| NEXT Oncology - Dallas | Irving | Texas | 75039 | Recruiting |
| NEXT Oncology - San Antonio | San Antonio | Texas | 78229 | Recruiting |
| University of Utah - Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | Recruiting |
| NEXT Virginia | Fairfax | Virginia | 22031 | Recruiting |
| Fred Hutchison Cancer Center | Seattle | Washington | 98195 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07207707, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2026 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07207707 live on ClinicalTrials.gov.